85,000 Shares in Charles River Laboratories International, Inc. $CRL Acquired by Caisse DE Depot ET Placement DU Quebec

Key Points

• Caisse DE Depot ET Placement DU Quebec has acquired a new investment in Charles River Laboratories International, purchasing 85,000 shares valued at approximately $12.8 million.
• Charles River Laboratories reported earnings of $3.12 per share, exceeding expectations, with revenue reaching $1.03 billion for the quarter.
• Analysts have set a consensus price target of $175.69 for Charles River Laboratories, with multiple upgrades in ratings and price objectives from various research firms.

Caisse DE Depot ET Placement DU Quebec purchased a new stake in Charles River Laboratories International, Inc. (NYSE:CRL - Free Report) during the 1st quarter, according to the company in its most recent disclosure with the SEC. The institutional investor purchased 85,000 shares of the medical research company's stock, valued at approximately $12,794,000. Caisse DE Depot ET Placement DU Quebec owned about 0.17% of Charles River Laboratories International as of its most recent SEC filing.

Other large investors have also modified their holdings of the company. Rothschild Investment LLC lifted its stake in shares of Charles River Laboratories International by 480.0% in the 1st quarter. Rothschild Investment LLC now owns 174 shares of the medical research company's stock valued at $26,000 after purchasing an additional 144 shares during the last quarter. Brooklyn Investment Group lifted its stake in Charles River Laboratories International by 93.5% during the 1st quarter. Brooklyn Investment Group now owns 178 shares of the medical research company's stock worth $27,000 after acquiring an additional 86 shares in the last quarter. Optiver Holding B.V. acquired a new position in Charles River Laboratories International during the 4th quarter worth about $37,000. HM Payson & Co. acquired a new position in Charles River Laboratories International during the 1st quarter worth about $31,000. Finally, Parallel Advisors LLC lifted its stake in Charles River Laboratories International by 83.7% during the 1st quarter. Parallel Advisors LLC now owns 474 shares of the medical research company's stock worth $71,000 after acquiring an additional 216 shares in the last quarter. Institutional investors and hedge funds own 98.91% of the company's stock.

Wall Street Analysts Forecast Growth

Several equities analysts recently issued reports on the company. Robert W. Baird increased their target price on Charles River Laboratories International from $118.00 to $140.00 and gave the stock a "neutral" rating in a research note on Thursday, May 8th. Cowen raised Charles River Laboratories International from a "hold" rating to a "buy" rating in a research note on Wednesday, May 14th. Wall Street Zen lowered Charles River Laboratories International from a "strong-buy" rating to a "buy" rating in a research note on Sunday, August 17th. Redburn Atlantic upgraded Charles River Laboratories International from a "neutral" rating to a "buy" rating and cut their price target for the stock from $188.00 to $182.00 in a report on Friday, May 23rd. Finally, Evercore ISI upped their price target on Charles River Laboratories International from $180.00 to $190.00 and gave the stock an "outperform" rating in a report on Friday, August 8th. Five analysts have rated the stock with a Buy rating, nine have assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, Charles River Laboratories International presently has a consensus rating of "Hold" and an average price target of $175.69.

Charles River Laboratories International Stock Up 0.0%

Shares of CRL traded up $0.07 during mid-day trading on Monday, reaching $163.29. The company's stock had a trading volume of 860,239 shares, compared to its average volume of 956,203. Charles River Laboratories International, Inc. has a 12-month low of $91.86 and a 12-month high of $230.02. The stock has a market cap of $8.04 billion, a PE ratio of -122.77, a price-to-earnings-growth ratio of 5.22 and a beta of 1.47. The company has a debt-to-equity ratio of 0.69, a current ratio of 1.36 and a quick ratio of 1.10. The company's 50 day moving average is $159.32 and its 200 day moving average is $148.75.

Charles River Laboratories International (NYSE:CRL - Get Free Report) last released its quarterly earnings data on Wednesday, August 6th. The medical research company reported $3.12 EPS for the quarter, beating analysts' consensus estimates of $2.50 by $0.62. Charles River Laboratories International had a positive return on equity of 15.74% and a negative net margin of 1.69%.The business had revenue of $1.03 billion for the quarter, compared to the consensus estimate of $983.76 million. During the same quarter in the prior year, the business posted $2.80 EPS. The business's revenue for the quarter was up .6% on a year-over-year basis. Equities analysts anticipate that Charles River Laboratories International, Inc. will post 9.36 EPS for the current fiscal year.

Insider Transactions at Charles River Laboratories International

In related news, EVP Joseph W. Laplume sold 800 shares of the firm's stock in a transaction that occurred on Monday, August 18th. The stock was sold at an average price of $157.60, for a total transaction of $126,080.00. Following the transaction, the executive vice president owned 24,116 shares in the company, valued at $3,800,681.60. This trade represents a 3.21% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. 1.30% of the stock is owned by corporate insiders.

Charles River Laboratories International Company Profile

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).